title: Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma.
abstract: We have recently shown that systemic administration of low molecular weight hyaluronan (LMW HA) significantly reduces colorectal carcinoma (CRC) growth in vivo. The elicited response is partially mediated by activated dendritic cells (DC). To potentiate the ability of DC loaded with whole tumor lysate (DC/TL) to induce immunity against CRC in mice, we aimed to study the effects of preconditioning DC with LMW HA for therapeutic vaccination. LMW HA improved maturation of ex vivo generated DC, increased IL-12, decreased IL-10 production, and enhanced a MLR activity in vitro. Although TNF-α showed a similar capacity to mature DC, preconditioning of DC/TL with LMW HA increased their ability to migrate in vitro toward CCL19 and CCL-21 in a CD44- and a TLR4-independent manner; this effect was superior to Poly(I:C), LPS, or TNF-α and partially associated with an increase in the expression of CCR7. Importantly, LMW HA dramatically enhanced the in vivo DC recruitment to tumor-regional lymph nodes. When these LMW HA-treated CRC tumor lysate-pulsed DC (DC/TL/LMW HA) were administered to tumor-bearing mice, a potent antitumor response was observed when compared to DC pulsed with tumor lysate alone and matured with TNF-α. Then, we showed that splenocytes isolated from animals treated with DC/TL/LMW HA presented a higher proliferative capacity, increased IFN-γ production, and secreted lower levels of the immunosuppressive IL-10. Besides, increased specific CTL response was observed in DC/TL/LMW HA-treated animals and induced long-term protection against tumor recurrence. Our data show that LMW HA is superior to other agents at inducing DC migration; therefore, LMW HA could be considered a new adjuvant candidate in the preparation of DC-based anticancer vaccines with potent immunostimulatory properties.
authors.affiliation: Gene Therapy Laboratory, School of Medicine, Austral University, Avenida Presidente Perón 1500 (B1629ODT) Derqui-Pilar, Buenos Aires, Argentina. laualaniz@yahoo.com.ar
authors.forename: Laura
authors.initials: L
authors.lastname: Alaniz
authors.forename: Manglio
authors.initials: M
authors.lastname: Rizzo
authors.forename: Mariana G
authors.initials: MG
authors.lastname: Garcia
authors.forename: Flavia
authors.initials: F
authors.lastname: Piccioni
authors.forename: Jorge B
authors.initials: JB
authors.lastname: Aquino
authors.forename: Mariana
authors.initials: M
authors.lastname: Malvicini
authors.forename: Catalina
authors.initials: C
authors.lastname: Atorrasagasti
authors.forename: Juan
authors.initials: J
authors.lastname: Bayo
authors.forename: Itziar
authors.initials: I
authors.lastname: Echeverria
authors.forename: Pablo
authors.initials: P
authors.lastname: Sarobe
authors.forename: Guillermo
authors.initials: G
authors.lastname: Mazzolini
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D002465:Cell Movement / Q000187:drug effects*; D002469:Cell Separation; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000628:therapy; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects* / Q000637:transplantation; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006820:Hyaluronic Acid / Q000276:immunology / Q000494:pharmacology*; D007167:Immunotherapy; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D006820:Hyaluronic Acid